Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE9: Presurgical 9-valent HPV Vaccination in Women Treated With LEEP
NCT03848039Phase 3Not yet recruiting
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in cervical intraepithelial neoplasia (CIN) and Cervical Cancer (CC) comparing Gardasil-9 with Placebo (2 arms). Primary endpoint: Cumulative recurrence of CIN2+ after conization at 5 years. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03848039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848039.